Medtronic lifts annual profit view on strong demand for medical devices
Adds company comment in paragraph 4, details from sales in paragraph 7-9, shares in paragraph 11
Nov 19 (Reuters) -Medtronic MDT.N lifted the lower end of its annual profit forecast for a second time on Tuesday, banking on sustained demand for its medical devices in the United States.
As negative impacts from foreign currency fluctuations abate,the company expects to report high-single-digit growth in adjusted earnings per share in the back half of the fiscal year, said Gary Corona, Medtronic's interim chief financial officer.
The Ireland-based company raised the lower end of its 2025 adjusted profit forecast to $5.44 per share from $5.42 earlier, keeping the upper end at $5.50. The new midpoint of $5.47 is slightly higher than analysts' estimates of $5.45, according to data compiled by LSEG.
Investors had set a high bar for results from medical device makers as the companies continue to benefit from healthy demand for non-urgent surgeries, especially among older Americans, over the last few quarters.
Peers Boston Scientific BSX.N and Abbott ABT.N had also raised their annual profit forecasts last month.
Medtronic's total revenue for the quarter ended Oct. 25 rose 5.3% to $8.40 billion, compared with estimates of $8.27 billion.
The heartdevices unit, its biggest revenue driver, posted a6.1% increase in sales to$3.10 billion, above estimates of $3.06 billion.
Thediabetes unit reported a12.4% jump to$686 million, while theneuroscience segment's sales rose7.1% to $2.45 billion, beating expectations.
Its medical surgical unit brought in$2.13 billion, in line with estimates.
The company posted adjusted profit of $1.26 per share for the second quarter, compared with estimatesof $1.25.
Its shareswere marginally lower inpremarket trading.
Reporting by Sriparna Roy and Mariam Sunny in Bengaluru; Editing by Devika Syamnath
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
